{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-084357","form_type":"8-K","ticker":"INVA","cik":"0001080014","company_name":"Innoviva, Inc.","filed_at":"2024-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.112091+00:00","generated_at":"2026-05-31T14:14:45.824521+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Innoviva Q2 2024: net loss $34.7M on investment fair-value hit; royalty revenue $67.2M","bullets":["GSK royalty revenue $67.2M vs $65.7M YoY; net product sales $21.7M (+38% YoY).","Net loss of $34.7M ($0.55 basic loss) due to $90.7M unfavorable change in equity investments.","License revenue $14.5M including $8M milestone from XACDURO approval in China.","Completed $100M share repurchase program; repurchased 0.4M shares in Q2 for $5.3M.","XACDURO approved in China; named preferred agent in 2024 IDSA guidance; XERAVA recommended by SIS guidelines."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-084357","json":"https://secwatch.observer/filing/0001104659-24-084357.json","markdown":"https://secwatch.observer/filing/0001104659-24-084357.md","text":"https://secwatch.observer/filing/0001104659-24-084357.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1080014/000110465924084357/0001104659-24-084357-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1080014/000110465924084357/tm2420507d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:14:45.824521+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}